Raymond Hohl, MD, PhD - Penn State Cancer Institute
Researcher Profile
Raymond Hohl, MD, PhD
University Professor in Oncology, Department of Medicine
Division of Hematology and Oncology
Professor, Department of Pharmacology
Division of Hematology and Oncology
Professor, Department of Pharmacology
Scientific Program:Next-Generation Therapies
Disease Teams:
Cancer Institute, Bone Marrow Transplantation Team
Cancer Institute, Leukemia and Lymphoma Team
Cancer Institute, Leukemia and Lymphoma Team
Research Interests
- Neoplasms
- Terpenes
- Therapeutics
- Lovastatin
- Proteins
- Prenylation
- Cell Line
- Diphosphonates
- Leukemia
- farnesyl pyrophosphate
- geranylgeranyl pyrophosphate
- Pharmacokinetics
Clinical Trials
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Blood and Bone Marrow Collection from Patients with Hematological Malignancies for Study of Anti-Tumor Immunity
Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
A Phase II, Multicenter, Randomized, Open-Label Trial of GEN1046 as monotherapy and in Combination with Anti-cancer Therapy in Subjects with Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer who failed first-line Standard of Care therapy with an Immune Checkpoint Inhibitor
A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C mutation (MRT849-001)
A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
NRG HN009- Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
S1914 A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC
A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries with Multiple Myeloma: A Study to Develop Evidence of Effectiveness for the Centers for Medicare and Medicaid Services (CMS)
Recent Publications
2024
Guare, EG, Hale, CM, Sivik, J, Lehman, E, Inoue, Y, Rakszawski, K, Songdej, N, Nickolich, M, Zheng, H, Naik, S, Claxton, D, Rybka, W, Hohl, R, Mineishi, S, Minagawa, K & Paules, CI 2024, 'The addition of doxycycline to fluoroquinolones for bacterial prophylaxis in autologous stem cell transplantation for multiple myeloma', Transplant Infectious Disease, vol. 26, no. 2, e14241. https://doi.org/10.1111/tid.14241
2022
ELOQUENT-1 investigators 2022, 'Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial', The Lancet Haematology, vol. 9, no. 6, pp. e403-e414. https://doi.org/10.1016/S2352-3026(22)00103-X
Manfredi, B, Neighbors, JD & Hohl, RJ 2022, 'Cytotoxic Effects of the Schweinfurthin Analog 5'-Methylschweinfurthin G in Malignant Plasma Cells', Pharmacology, vol. 107, no. 9-10, pp. 510-523. https://doi.org/10.1159/000525299
Cioccio, J, Rakszawski, K, Zheng, H, Nickolich, M, Naik, S, Wirk, B, Rybka, W, Ehmann, C, Silar, B, Vajdic, C, Shah, N, Tuanquin, L, Greiner, R, Brown, V, Hohl, R, Claxton, D, Mineishi, S, Minagawa, K & Shike, H 2023, 'Donor HLA mismatch promotes full donor T-cell chimerism in the allogeneic stem cell transplant with reduced-intensity conditioning and post-transplant cyclophosphamide GVHD prophylaxis', Annals of Hematology, vol. 102, no. 3, pp. 613-620. https://doi.org/10.1007/s00277-022-05077-2
Shah, N, Cioccio, J, Rakszawski, K, Zheng, H, Nickolich, M, Naik, S, Wirk, B, Rybka, W, Ehmann, C, Silar, B, Vajdic, C, Mierski, J, Zhou, S, Shike, H, Greiner, R, Brown, V, Hohl, R, Claxton, D, Mineishi, S, Minagawa, K & Tuanquin, L 2022, 'Low-dose total body irradiation promotes T-cells donor chimerism in reduced-intensity/non-myeloablative allogeneic stem cell transplant with post-transplant cyclophosphamide', Leukemia Research, vol. 123, 106969. https://doi.org/10.1016/j.leukres.2022.106969
Zhao, C, Bartock, M, Jia, B, Shah, N, Claxton, DF, Wirk, B, Rakszawski, KL, Nickolich, MS, Naik, SG, Rybka, WB, Ehmann, WCC, Hohl, RJ, Valentin, J, Bernas-Peterson, M, Gerber, EM, Zimmerman, M, Mierski, JA, Mineishi, S & Zheng, H 2022, 'Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant', Journal of Hematology and Oncology, vol. 15, no. 1, 64. https://doi.org/10.1186/s13045-022-01287-3
Weissenrieder, JS, Weissenkampen, JD, Reed, JL, Green, MV, Zheng, C, Neighbors, JD, Liu, DJ & Hohl, RJ 2022, 'RNAseq reveals extensive metabolic disruptions in the sensitive SF-295 cell line treated with schweinfurthins', Scientific reports, vol. 12, no. 1, 359. https://doi.org/10.1038/s41598-021-04117-7
Zhang, R, Neighbors, JD, Schell, TD & Hohl, RJ 2022, 'Schweinfurthin induces ICD without ER stress and caspase activation', OncoImmunology, vol. 11, no. 1, 2104551. https://doi.org/10.1080/2162402X.2022.2104551
Koubek, EJ, Weissenrieder, JS, Ortiz, LE, Nwogu, N, Pham, AM, Weissenkampen, JD, Reed, JL, Neighbors, JD, Hohl, RJ & Kwun, HJ 2022, 'Therapeutic Potential of 5′-Methylschweinfurthin G in Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma', Viruses, vol. 14, no. 9, 1848. https://doi.org/10.3390/v14091848
2021
Weissenrieder, JS, Reed, JL, Moldovan, GL, Johnson, MT, Trebak, M, Neighbors, JD, Mailman, RB & Hohl, RJ 2021, 'Antipsychotic drugs elicit cytotoxicity in glioblastoma multiforme in a calcium-dependent, non-D2 receptor-dependent, manner', Pharmacology Research and Perspectives, vol. 9, no. 3, e00689. https://doi.org/10.1002/prp2.689
2020
Zheng, H, Mineishi, S, Claxton, D, Zhu, J, Zhao, C, Jia, B, Ehmann, WC, Rybka, WB, Naik, S, Songdej, N, Drabick, JJ & Hohl, RJ 2021, 'A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia', American Journal of Hematology, vol. 96, no. 2, pp. E46-E50. https://doi.org/10.1002/ajh.26043
Bluethmann, SM, Wang, M, Wasserman, E, Chen, C, Zaorsky, NG, Hohl, RJ & McDonald, AC 2020, 'Prostate cancer in Pennsylvania: The role of older age at diagnosis, aggressiveness, and environmental risk factors on treatment and mortality using data from the Pennsylvania Cancer Registry', Cancer medicine, vol. 9, no. 10, pp. 3623-3633. https://doi.org/10.1002/cam4.3003
McDonald, AC, Wasserman, E, Lengerich, EJ, Raman, JD, Geyer, NR, Hohl, RJ & Wang, M 2020, 'Prostate cancer incidence and aggressiveness in appalachia versus non-appalachia populations in Pennsylvania by urban-rural regions, 2004–2014', Cancer Epidemiology Biomarkers and Prevention, vol. 29, no. 7, pp. 1365-1373. https://doi.org/10.1158/1055-9965.EPI-19-1232
Wang, M, Wasserman, E, Geyer, N, Carroll, RM, Zhao, S, Zhang, L, Hohl, R, Lengerich, EJ & McDonald, AC 2020, 'Spatial patterns in prostate Cancer-specific mortality in Pennsylvania using Pennsylvania Cancer registry data, 2004-2014', BMC Cancer, vol. 20, no. 1, 394. https://doi.org/10.1186/s12885-020-06902-5